Intercellular adhesion molecules and chemotaxic factors in the pathogenesis of multiple sclerosis;Moléculas de adhesión intercelular y factores quimiotácticos en la patogenia de la esclerosis múltiple

Revista de Neurologia

Volumn 35, Issue 10, 2002, Pages 985-993

  Gonzalez Amaro R ^a   Sánchez Madrid, Francisco ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Chemokines; Inflammation; Integrins; Lymphocytes

Indexed keywords

BETA1 INTEGRIN; CHEMOKINE; CHEMOTACTIC FACTOR; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; RANTES; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALITIS; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; DEMYELINATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; LYMPHOCYTE; MONOCYTE; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PROTEIN EXPRESSION; REVIEW;

EID: 0037121401     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3510.2002379     Document Type: Review

References (97)

1. Fernández O. Enfermedades desmielinizantes del sistema nervioso central. In Farreras P, Rozman C, eds. Medicina Interna. Madrid: Harcourt; 2000. p. 1652-62.
2. Weinshenker BG. Epidemiology of multiple sclerosis. In Riggs JE, ed. Neurologic Clinics: Neurepidemiology. Philadelphia: Saunders; 1996. p. 291-308.
3. Prineas JW. The neuropathology of multiple sclerosis. In Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, eds. Handbook of Clinical Neurology, Demyelinating Diseases. New York: Elsevier; 1985. p. 213-57.
4. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: Distribution of T cell subsets within active chronic lesions. Science 1983; 219: 308-10.
5. Mosmann TR, Coffman RL. Th1 and Th2 cells: Different patterns of lymphocyte secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
6. Alvord EC. Experimental Allergic Encephalomyelitis: A Useful Model for Multiple Sclerosis. New York: Liss; 1984.
7. Paterson PY. Transfer of allergic encephalomyelitis in rats by mean of lymph node cells. J Exp Med 1960; 111: 119-33.
8. Ben-Nun A, Wekerle H, Gohen I. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981; 11: 195-9.
9. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992; 10: 153-87.
10. González-Amaro R, Díaz-González F, Sánchez-Madrid F. Adhesion molecules in inflammatory diseases. Drugs 1998; 56: 977-88.
11. González-Amaro R, Sánchez-Madrid F. Cell adhesion molecules: Selectins and integrins. Crit Rev Immunol 1999; 19: 389-429.
12. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptor: The role of integrins, cadherins, immunoglobulin cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 199-263.
13. Corbi AL. Leukocyte Integrins: Structure, Expression and Function. London: Springer-RG Landes; 1996.
14. von Andrian UH, Mackay CR. T cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020-34.
15. Anderson DC, Springer TA. Leukocyte adhesion deficiency: An inherited defect in the Mac-1, LFA-1 and p 150/95 glycoproteins Annu Rev Med 1987; 38: 175-94.
16. Karsan A, Cornejo CJ, Winn RK, Schwartz BR, Way W, Lannir N, et al. Leukocyte adhesion deficiency type 11 is a generalized defect of the novo GDP-fucose biosynthesis. J Clin Invest 1998; 101: 2438-45.
17. Archelos JJ, Jung S, Rinner W, Lassmann H, Miyasaka M, Hartung HP. Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. J Neurol Sci 1998; 159: 127-34.
18. Mossner R, Fassbender K, Kuhnen J, Schwartz A, Hennerici M. Circulating L-selectin in multiple sclerosis patients with active gadolinium-enhancing brain plaques. J Neuroimmunol 1996; 65: 61-5.
19. Vora AJ, Kidd D, Miller DH, Perkin GD, Hughes RA, Ellis BA, et al. Lymphocyte-endothelial cell interactions in multiple sclerosis: Disease specificity and relationship to circulating tumor necrosis factor-alpha and soluble adhesion molecules. Mult Scler 1997; 3: 171-9.
20. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging. Ann Neurol 1995; 38: 186-93.
21. Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV. Soluble 1CAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993; 43: 2331-5.
22. Rieckman P, Altenhofen B, Riegel A, Bandewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997; 41: 326-33.
23. Mossner R, Fassbender K, Kuhnen J, Schwartz A, Hennerici M. Vascular cell adhesion molecule: A new approach to detect endothelial cell activation in MS and encephalitis in vivo. Acta Neurol Scand 1996; 93: 118-22.
24. Dopp JM, Breneman SM, Olschowka JA. Expression of ICAM-1, VCAM-1, L-selectin, and leukosialin in the mouse central nervous system during the induction and remission stages of the experimental allergic encephalomyelitis. J Neuroimmunol 1994; 54: 129-44.
25. Sipkins DA, Gijbels K, Tropper FD, Berdnarsky M, Li KC, Steinman L. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J Neuroimmunol 2000; 104: 1-9.
26. Engelhardt B, Vestweber D, Hallmann R, Schulz ME, P selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 1997; 90: 4459-72.
27. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (1CAM-1) in cellular immune reactions in human central nervous system. Am J Pathol 1990; 136: 1309-16.
28. Bo L, Peterson JW, Mork S, Hoffman PA, Gallatin WM, Ransohoff RM, et al. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta2 integrin LFA-I in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 1060-72.
29. Previtali SC, Archelos JJ, Hartung HP. Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha. Am J Pathol 1997; 151: 1425-35.
30. Laschinger M, Engelhardt B. Interaction of alpha4-integrin with VCAM-1 in involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in the transendothelial migration in vitro. J Neuroimmunol 2000; 102: 32-43.
31. De-Carvalho MC, Chimelli LM, Quirico-Santos T. Modulation of fibronectin expression in the nervous central system of Lewis rats with experimental autoimmune encephalomyelitis. Braz J Med Biol Res 1999; 32: 583-92.
32. Kanwar JR, Harrison JE, Wang D, Leung E, Mueller W, Wagner M, et al. Beta7 integrins contribute to demyelinating disease of the central nervous system. J Neuroimmunol 2000; 103: 146-52.
33. Haskard DO. Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol 1995; 7: 229-34.
34. Postigo AA, Teixidó J, Sánchez-Madrid F. The alpha4-beta1/VCAM-1 adhesion pathway in physiology and disease. Res Immunol 1993; 144: 723-35.
35. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, Hoch G. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest 1998; 102: 2096-105.
36. Murphy PM. The molecular biology of chemoattractant receptors. Annu Rev Immunol 1994; 12: 593-633.
37. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994; 6:865-73.
38. Baggiolini M, Dewald B, Moser B. Human chemokines: An update. Annu Rev Immunol 1997; 15: 675-705.
39. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 21742.
40. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector and memory immune responses. Annu Rev Immunol 2000; 18: 593-620.
41. Zhang GX, Baker CM, Kolson DL, Rostami AM. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler 2000; 6: 3-13.
42. Karpus WJ, Ransohoff RM. Chemokine regulation of experimental autoimmune encephalomyelitis: Temporal and spatial expression patterns govern disease pathogenesis. J Immunol 1998; 161: 2667-71.
43. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 167-76.
44. Boven LA, Montagne L, Nottet HS, De-Groot CJ. Macrophage inflammatory protein-1 alpha (MIP-1 alpha), MIP-1 beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin Exp Immunol 2000; 122: 257-63.
45. van der Voorn P, Tekstra J, Beelen RH, Tensen CP, van der Valk, de Groot CJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999; 154: 45-51.
46. Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, et al. Expression of functional multiple chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 2000; 97: 591-600.
47. Iarlori C, Reale M, Lugaresi A, de Luca G, Bonanni L, di Iorio A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000; 107: 100-7.
48. Zang YC, Samanta AK, Halder JB, Hong J, Tejeda-Simon MV, Rivera VM, et al. Aberrant T cell migration towards RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 2000; 123: 1874-82.
49. Luo Y, Fischer FR, Hancock WW, Dorf ME. Macrophage inflammatory protein-2 and KC induce chemokine production by mouse astrocytes. J Immunol 2000; 165: 4015-23.
50. McManus CM, Weidenheim K, Woodman SE, Nunez J, Hesselgesser J, Nath A, et al. Chemokine and chemokine-receptor expression in human glial elements: Induction by the HIV protein, Tat, and chemokine autoregulation. Am J Pathol 2000; 156: 1441-53.
51. Andjelkovic AV, Kerkovich D, Pachter JS. Monocyte: Astrocyte interactions regulate MCP-1 expression in both cell types. J Leukoc Biol 2000; 68: 545-52.
52. Otto VI, Heinzel-Pleines UE, Gloor SM, Trentz O, Kossmann T, Morganti-Kossmann MC. SICAM-1 and TNF-alpha induce MIP-2 with distinct kinetics in astrocytes and brain microvascular endothelial cells. J Neurosci Res 2000; 60: 733-42.
53. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous tissue. J Neuroimmunol 2000; 108: 192-200.
54. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptors, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26: 133-42.
55. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR) 2. J Exp Med 2000; 192: 1075-80.
56. Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CJ, Hancock WW. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000; 30: 2372-7.
57. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30: 1410-5.
58. Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R, et al. CC-chemokine receptor5 polymorphism and age of onset in familial multiple sclerosis. Multiple sclerosis genetics group. Immunogenetics 2000; 51: 281-8.
59. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 2001; 112: 174-80.
60. Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME. Modulation of experimental autoimmune encephalomyelitis: Effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 2000; 110: 195-208.
61. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, et al. Neurotactin, a membrane-anchored chemokine up-regulated in brain inflammation. Nature 1997; 387: 611-7.
62. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptor on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A 2000; 97: 8075-80.
63. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR-expressing cells is independent of G-protein activation. J Biol Chem 1999; 274: 10053-8.
64. Chapman GA, Moores KE, Gohil J, Berkhout TA, Patel L, Green P. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol 2000; 392: 189-95.
65. Zujovic V, Benavides J, Vige X, Carter C, Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 2000; 29: 305-15.
66. Liu MT, Chen BP, Oertel P, Buchmeier MJ, Armstrong D, Hamilton TA, et al. The T cell chemoattractant 1FN-inducible protein 10 is essential in host defense against viral-induced neurelogic disease. J Immunol 2000; 165: 2327-30.
67. González-Amaro R, Sánchez-Madrid F. Drugs, inflammation and cell adhesion receptors. Expert Opin Pharmacol 2001; [En prensa].
68. Yednock TA, Cannon C, Fritz LC, Sánchez-Madrid F, Stemman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4 beta1 integrin. Nature 1992; 356: 63-6.
69. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999; 96: 6896-901.
70. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, et al. A monoclonal antibody to alpha4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 1-10.
71. Keszthelyi E, Karlik S, Hyduk S, Rice GP, Gordon G, Yednock TA, et al. Evidence for a prolonged role of alpha 4 integrin throughout active experimental allergic encephalomyelitis. Neurology 1996; 47: 1053-9.
72. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, et al. Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3-16.
73. Kawai K, Kobayashi Y, Shiratori M, Sobue G, Tamatani T, Miyasaka M, et al. Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats. Cell Immunol 1996; 171: 262-8.
74. Huitinga I, Damoiseaux JG, Dopp EA, Dijkstra CD. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23: 709-15.
75. Rose L, Richards TL, Peterson J, Petersen R, Alvord EC Jr. Resolution of CNS lesions following treatment of experimental allergic encephalomyelitis in macaques with monoclonal antibody to the CD18 leukocyte integrin. Mult Scler 1997; 2: 259-66.
76. Kobayashi Y, Kawai K, Honda H, Tomida S, Niimi N, Tamatani T, et al. Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. Cell Immunol 1995; 164: 295-305.
77. Archelos JJ, Jung S, Maurer M, Schmied M, Lassmann H, Tamatani T, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993; 34: 145-54.
78. Willenborg DO, Simmons RD, Tamatani T, Miyasaka M. ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J Neuroimmunol 1993; 45: 147-54.
79. Canella B, Cross AH, Raine CS. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. J Neuroimmunol 1993; 46: 43-55.
80. Jung S, Toyka K, Hartung HP. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995; 25: 1391-8.
81. Williams KC, Zhao W, Politopoulos G, Male D, Hickey WF. Inhibition of experimental allergic encephalomyelitis with an antibody that recognizes a novel antigen expressed on lymphocytes, endothelial cells and microglia. Lab Invest 2000; 80: 313-26.
82. Nataf S, Louboutin JP, Chabannes D, Feve JR, Muller JY. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol Scand 1993; 88: 97-9.
83. Folcik VA, Smith T, O'Bryant S, Kawczak JA, Zhu B, Sakurai H, et al. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J Neuroimmunol 1999; 97: 119-28.
84. González-Amaro R, Portales-Pérez DP, Baranda L, Redondo JM, Martínez-Martínez S, Yañez-Mo M, et al. Pentoxifylline inhibits adhesion and activation of T lymphocytes. J Immunol 1998; 161: 65-72.
85. Trojano M, Defazio G, Avolio C, Paolicelli D, Giuliani F, Giorelli M, et al. Effects of rIFN-beta-lb on serum circulating ICAM-1 in relapsing-remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. J Neurovirol 2000; 6 (Suppl 2): S47-51.
86. Sun JB, Xiao BG, Lindblad M, Li BL, Link H, Czerkinsky C, et al. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-beta-secreting cells and suppressing chemokine expression. Int Immunol 2000; 12: 1449-57.
87. Pette M, Pette DF, Muraro DA, Farnon E, Martin R, McFarland HF. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T helper type 1 lymphocytes. Neurology 1997; 49: 385-92.
88. Ransohoff RM, Bacon KB. Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs 2000; 9: 1079-97.
89. Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000; 275: 19000-8.
90. Youssef S, Wildbaum G, Maor G, Lanir N, Gour-Lavie A, Grabie N, et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161: 3870-9.
91. Youssef S, Widhaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1 alpha and MCP-1 naked vaccines. J Autoimmun 1999; 13: 21-9.
92. Constatin G, Brocke S, Izikson A, Laudanna C, Butcher EC. Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur J Immunol 1998; 28: 3523-9.
93. Constatin G, Laudanna C, Brocke S, Butcher EC. Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor. J Immunol 1999; 162: 1144-9.
94. Defazio G, Nico B, Trojano M, Ribatti D, Giorelli M, Richiutti F, et al. Inhibition of protein kinase C counteracts TNF-alpha-induced intercellular adhesion molecule-1 expression and fluis phase endocytosis on brain microvascular endothelial cells. Brain Res 2000; 863: 245-8.
95. Hyduk SJ, Karlik SJ. Apoptotic cells are present in the CNS throughout acute and chronic-progressive EAE in the absence of clinical recovery. J Neuropathol Exp Neurol 1998; 57: 602-14.
96. Okuda Y, Sakoda S, Fujimura H, Nagata S, Yanagihara T, Bernard CC. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2000; 275: 164-8.
97. Korner H, Goodsall AL, Lemckert FA, Scallon BJ, Ghrayeb J, Ford AL, et al. Unimpaired autoreactive T cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1995; 92: 11066-70.